What is Aerie Pharmaceuticals' stock symbol?
Aerie Pharmaceuticals trades on the NASDAQ under the ticker symbol "AERI."
Where is Aerie Pharmaceuticals' stock going? Where will Aerie Pharmaceuticals' stock price be in 2017?
13 brokers have issued 1 year price objectives for Aerie Pharmaceuticals' shares. Their predictions range from $48.00 to $70.00. On average, they expect Aerie Pharmaceuticals' share price to reach $56.85 in the next twelve months.
When will Aerie Pharmaceuticals announce their earnings?
Aerie Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 27th 2017.
What are analysts saying about Aerie Pharmaceuticals stock?
Here are some recent quotes from research analysts about Aerie Pharmaceuticals stock:
According to Zacks Investment Research, "Aerie is positive on the efforts in developing its pipeline candidates. Aerie has filed a new drug application (NDA) for its lead candidate, Rhopressa, in the U.S. in the Sep 2016 for treatment of glaucoma or ocular hypertension. A potential approval and successful commercialization of the drug will significantly boost the company’s growth prospects as glaucoma is one of the largest segments in the global ophthalmic market. We are also positive with Aerie’s second late-stage glaucoma candidate, Roclatan, which is being evaluated for lowering intraocular pressure in patients suffering from open-angle glaucoma and ocular hypertension. However, with no approved product in its portfolio, any regulatory setback would have an adverse impact on the stock. Estimates have remained mostly stable ahead of the company’s Q3 earnings release. However, the company has a negative record of earnings surprises in recent quarters." (11/3/2016)
Brean Capital analysts commented, "At yesterday’s investor day, Aerie painted a clearer portrait of the current standard of care and competitive glaucoma treatment environment. Management also provided further insight into the recent Mercury 1 data for Roclatan, a closer look at how to measure the effectiveness of glaucoma treatment with added perspective from a former physician, as well as revisited what the company’s future value adding drivers will be and articulated the international strategy. We took the opportunity to dive deeper into our model, taking into account potential future European launches and Japanese clinical trials." (10/6/2016)
Cantor Fitzgerald analysts commented, "Even Better: When comparing the Phase 3 results with an earlier, smaller trial, the combination drug worked even better than its ingredients. Intraocular pressure (IOP) was reduced, on average to 15-16mmHg at all nine time points measured over a 90-day period. The lowering was 1-3mmHg higher than observed with the components, latanoprost and Rhopressa. The difference, as disclosed in a slide deck presented, but not in the press release, was statistically significant with a p value of =35% reduction in IOP." (9/15/2016)
Who owns Aerie Pharmaceuticals stock?
Aerie Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Deerfield Management Co. (5.51%), Foresite Capital Management III LLC (4.79%), Foresite Capital Management II LLC (4.72%), Orbimed Advisors LLC (4.48%), State Street Corp (2.46%) and Fred Alger Management Inc. (0.75%). Company insiders that own Aerie Pharmaceuticals stock include Anand Mehra, Foresite Capital Fund Ii, LP and Geoffrey M Duyk.
Who sold Aerie Pharmaceuticals stock? Who is selling Aerie Pharmaceuticals stock?
Aerie Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Acuta Capital Partners LLC, Wall Street Associates, Putnam Investments LLC, Foresite Capital Management III LLC, Foresite Capital Management II LLC, Alyeska Investment Group L.P., FMR LLC and State Board of Administration of Florida Retirement System. Company insiders that have sold Aerie Pharmaceuticals stock in the last year include Foresite Capital Fund Ii, LP and Geoffrey M Duyk.
Who bought Aerie Pharmaceuticals stock? Who is buying Aerie Pharmaceuticals stock?
Aerie Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Deerfield Management Co., State Street Corp, Genovese Burford & Brothers Wealth & Retirement Plan Management LLC, Senzar Asset Management LLC, Fred Alger Management Inc., Perceptive Advisors LLC and Russell Investments Group Ltd..
How do I buy Aerie Pharmaceuticals stock?
Shares of Aerie Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Aerie Pharmaceuticals stock cost?
One share of Aerie Pharmaceuticals stock can currently be purchased for approximately $44.25.